Experimental immunotherapy of mice with transplanted MC-rhabdomyosarcoma resistant to doxorubicin.
OBJECTIVE
To compare the sensitivity of doxorubicin (DOX) sensitive and DOX-resistant MC-rhabdomyosarcoma (MC-RMS) cells to the action of lymphokine-activated cells (LAC).


RESULTS
In vitro investigations showed that LAC received from the fraction of adherent lymphocytes possess the highest activity against DOX-resistant tumor cells, and LAC from lymphocytes of total pool--against DOX-resistant tumor cells pretreated with DOX at a low dose. Adoptive immunotherapy of MC-RMS in vivo showed the highest efficacy in the cases of LAC intratumoral injection and the one combined with intraperitoneal administration of DOX at a low dose (increase of survival time by 14% and 25%, respectively).


CONCLUSIONS
Adoptive in vivo therapy of DOX-resistant Mh-RMS is effective if LAC or their combination with DOX at a low dose are administered.
Berezhnaya
Ninel M
NM
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv 03022, Ukraine. berezh@onconet.kiev.ua
Kovalchuk
Elena V
EV
Vinnichuk
Yulya D
YD
Spivak
Svetlana I
SI
Belova
Oxana B
OB
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D016219:Immunotherapy, Adoptive; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology* / Q000637:transplantation; D016131:Lymphocyte Subsets / Q000276:immunology* / Q000637:transplantation; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D012208:Rhabdomyosarcoma / Q000276:immunology / Q000473:pathology / Q000628:therapy
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin